TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

National Framework Agreement for the supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England

Pharmaceutical products
UK
Published value
Not published
Submission deadline Not published
Lots published49
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: The NHS Commissioning Board (operating under the name of NHS England): "National Framework Agreement for the supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England". Published status: complete. Published value: Value not published. 49 published lots. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityThe NHS Commissioning Board (operating under the name of NHS England)Scope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: The NHS Commissioning Board (operating under the name of NHS England)
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for The NHS Commissioning Board (operating under the name of NHS England). These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
46Bids / Report
1.7% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 829 active published awards; 827 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityThe NHS Commissioning Board (operating under the name of NHS England)
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSFramework
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published28 Apr 2021, 16:29 BST
Last source update28 Apr 2021, 16:29 BST
Recurring procurementNot published
ClassificationPharmaceutical products
Delivery area
UK
OCIDocds-h6vhtk-02ab4a
What is being bought
NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. Period of framework agreement: 1 April 2021 to 31 March 2022 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
What changed
From the official release history
  1. Status changed to complete
    28 Apr 2021, 16:29 BST
  2. Official notice release published
    28 Apr 2021, 16:29 BST
  3. Buyer information updated
    28 Apr 2021, 16:29 BST
Lots and requirements (49)
Published by the contracting authority
  • Lot 1 · #1
    Atezolizumab - Lot 1 
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 2 · #10
    Cyclophosphamide Syringes - Lot 10
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 3 · #11
    Cyclophosphamide Bags - Lot 11
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 4 · #12
    Cytarabine - Lot 12
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 5 · #13
    Docetaxel - Lot 13
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 6 · #14
    Doxorubicin - Lot 14
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 7 · #15
    Epirubicin - Lot 15
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 8 · #16
    Fludarabine Syringes - Lot 16
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 9 · #17
    Fludarabine Bags - Lot 17
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 10 · #18
    Fluorouracil Syringes - Lot 18
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 11 · #19
    Fluorouracil Bags - Lot 19
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 12 · #2
    Bevacizumab (Avastin) - Lot 2
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 13 · #20
    Fluorouracil in Elastomeric Devices (Folfusor SV0.5) - Lot 20
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 14 · #21
    Fluorouracil in Elastomeric Devices (Folfusor SV2.5) - Lot 21
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 15 · #22
    Fluorouracil in Elastomeric Devices (Folfusor LV1.5) - Lot 22
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 16 · #23
    Fluorouracil in Elastomeric Devices (Folfusor LV5) - Lot 23
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 17 · #24
    Fluorouracil in Elastomeric Devices (Autofuser 2.5ml/hr) - Lot 24
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 18 · #25
    Fluorouracil in Elastomeric Devices (Autofuser 2ml/hr) - Lot 25
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 19 · #26
    Fluorouracil in Elastomeric Devices (Surefuser) - Lot 26
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 20 · #27
    Ganciclovir - Lot 27
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 21 · #28
    Gemcitabine - Lot 28
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 22 · #3
    Bevacizumab (Zirabev) - Lot 3 
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 23 · #30
    Irinotecan - Lot 30
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 24 · #31
    Methotrexate - Lot 31
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 25 · #32
    Nivolumab - Lot 32
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 26 · #33
    Obinutuzumab - Lot 33
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 27 · #34
    Oxaliplatin - Lot 34
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 28 · #35
    Paclitaxel - Lot 35
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 29 · #36
    Panitumumab - Lot 36
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 30 · #37
    Pembrolizumab - Lot 37
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 31 · #38
    Pemetrexed - Lot 38
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 32 · #39
    Pertuzumab - Lot 39
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 33 · #4
    Bevacizumab (Aybintio) - Lot 4
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 34 · #40
    Rituximab (Mabthera) - Lot 40
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 35 · #41
    Rituximab (Rixathon) - Lot 41
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 36 · #42
    Rituximab (Truxima) - Lot 42
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 37 · #43
    Trastuzumab (Herceptin) - Lot 43
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 38 · #44
    Trastuzumab (Herzuma) - Lot 44
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 39 · #45
    Trastuzumab (Kanjinti) - Lot 45
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 40 · #46
    Trastuzumab (Ontruzant) - Lot 46
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 41 · #47
    Trastuzumab (Trasimera) - Lot 47
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 42 · #48
    Vinblastine - Lot 48
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 43 · #49
    Vincristine - Lot 49
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 44 · #5
    Bleomycin - Lot 5
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 45 · #50
    Vinorelbine - Lot 50
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 46 · #6
    Bortezomib - Lot 6
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 47 · #7
    Carboplatin - Lot 7
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 48 · #8
    Cetuximab - Lot 8
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 49 · #9
    Cisplatin - Lot 9
    cancelled
    Published valueNot published
    NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    28 Apr 2021, 16:29 BST
  2. Award active
    Not published · Not published
  3. Award active
    Not published · Not published
  4. Award active
    Not published · Not published
  5. Award active
    Not published · Not published
  6. Award active
    Not published · Not published
  7. Award active
    Not published · Not published
  8. Award active
    Not published · Not published
  9. Award active
    Not published · Not published
  10. Award active
    Not published · Not published
  11. Award active
    Not published · Not published
  12. Award active
    Not published · Not published
  13. Award active
    Not published · Not published
  14. Award active
    Not published · Not published
  15. Award active
    Not published · Not published
  16. Award active
    Not published · Not published
  17. Award active
    Not published · Not published
  18. Award active
    Not published · Not published
  19. Award active
    Not published · Not published
  20. Award active
    Not published · Not published
  21. Award active
    Not published · Not published
  22. Award active
    Not published · Not published
  23. Award active
    Not published · Not published
  24. Award active
    Not published · Not published
  25. Award active
    Not published · Not published
  26. Award active
    Not published · Not published
  27. Award active
    Not published · Not published
  28. Award active
    Not published · Not published
  29. Award active
    Not published · Not published
  30. Award active
    Not published · Not published
  31. Award active
    Not published · Not published
  32. Award active
    Not published · Not published
  33. Award active
    Not published · Not published
  34. Award active
    Not published · Not published
  35. Award active
    Not published · Not published
  36. Award active
    Not published · Not published
  37. Award active
    Not published · Not published
  38. Award active
    Not published · Not published
  39. Award active
    Not published · Not published
  40. Award active
    Not published · Not published
  41. Award active
    Not published · Not published
  42. Award active
    Not published · Not published
  43. Award active
    Not published · Not published
  44. Award active
    Not published · Not published
  45. Award active
    Not published · Not published
  46. Award active
    Not published · Not published
  47. Award active
    Not published · Not published
  48. Award active
    Not published · Not published
  49. Award active
    Not published · Not published
  50. Award active
    Not published · Not published
  51. Award active
    Not published · Not published
  52. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  53. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  54. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  55. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  56. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  57. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  58. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  59. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  60. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  61. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  62. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  63. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  64. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  65. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  66. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  67. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  68. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  69. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  70. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  71. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  72. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  73. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  74. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  75. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  76. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  77. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  78. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  79. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  80. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  81. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  82. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  83. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  84. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  85. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  86. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  87. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  88. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  89. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  90. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  91. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  92. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  93. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  94. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  95. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  96. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  97. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  98. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  99. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  100. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
  101. Contract active
    Signed 18 Mar 2021, 00:00 GMT · £1
Commercial outcome and competition
Awards
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
Quantum Aseptic Services
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
ITH Pharma
Not published · Not published · active
Quantum Aseptic Services
Not published · Not published · active
Quantum Aseptic Services
Not published · Not published · active
ITH Pharma
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
ITH Pharma
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
ITH Pharma
Not published · Not published · active
ITH Pharma
Not published · Not published · active
ITH Pharma
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
ITH Pharma
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
ITH Pharma
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
ITH Pharma
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
ITH Pharma
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
Quantum Aseptic Services
Not published · Not published · active
ITH Pharma
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
ITH Pharma
Not published · Not published · active
ITH Pharma
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
Quantum Aseptic Services
Not published · Not published · active
ITH Pharma
Not published · Not published · active
Baxter Healthcare Ltd
Not published · Not published · active
Qualasept Ltd t/a Bath ASU
Not published · Not published · active
Contracts
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Contract
£1 · signed 18 Mar 2021, 00:00 GMT · active
Bid statistics
bids: 4 (lot 1)
bids: 4 (lot 1)
bids: 4 (lot 1)
bids: 4 (lot 1)
electronicBids: 4 (lot 1)
electronicBids: 4 (lot 1)
electronicBids: 4 (lot 1)
electronicBids: 4 (lot 1)
foreignBidsFromEU: 4 (lot 1)
foreignBidsFromEU: 4 (lot 1)
foreignBidsFromEU: 4 (lot 1)
foreignBidsFromEU: 4 (lot 1)
foreignBidsFromNonEU: 0 (lot 1)
foreignBidsFromNonEU: 0 (lot 1)
foreignBidsFromNonEU: 0 (lot 1)
foreignBidsFromNonEU: 0 (lot 1)
smeBids: 1 (lot 1)
smeBids: 1 (lot 1)
smeBids: 1 (lot 1)
smeBids: 1 (lot 1)
bids: 3 (lot 10)
bids: 3 (lot 10)
electronicBids: 3 (lot 10)
electronicBids: 3 (lot 10)
foreignBidsFromEU: 3 (lot 10)
foreignBidsFromEU: 3 (lot 10)
foreignBidsFromNonEU: 0 (lot 10)
foreignBidsFromNonEU: 0 (lot 10)
smeBids: 1 (lot 10)
smeBids: 1 (lot 10)
bids: 3 (lot 11)
electronicBids: 3 (lot 11)
foreignBidsFromEU: 3 (lot 11)
foreignBidsFromNonEU: 0 (lot 11)
smeBids: 1 (lot 11)
bids: 3 (lot 12)
electronicBids: 3 (lot 12)
foreignBidsFromEU: 3 (lot 12)
foreignBidsFromNonEU: 0 (lot 12)
smeBids: 1 (lot 12)
bids: 2 (lot 13)
electronicBids: 2 (lot 13)
foreignBidsFromEU: 2 (lot 13)
foreignBidsFromNonEU: 0 (lot 13)
smeBids: 0 (lot 13)
bids: 3 (lot 14)
electronicBids: 3 (lot 14)
foreignBidsFromEU: 3 (lot 14)
foreignBidsFromNonEU: 0 (lot 14)
smeBids: 1 (lot 14)
Buyer and organisations in this procedure

The NHS Commissioning Board (operating under the name of NHS England)

Contracting authority GB-FTS-2505
View buyer profile

  • The NHS Commissioning Board (operating under the name of NHS England)
    buyer
    centralPurchasingBody

    2nd Floor, Rutland House, Runcorn, UK, WA7 2ES
    philip.grieve@nhs.net

  • Baxter Healthcare Ltd
    supplier

    Wallingford Road, Compton, Newbury, Berkshire, RG20 7QW, Newbury, UK, RG20 7QW

  • ITH Pharma
    supplier

    Unit 4, Premier Park, London, London, UK, NW10 7NZ

  • Qualasept Ltd t/a Bath ASU
    supplier

    3 Corsham Science Park, Park Lane, Corsham, Wiltshire, Corsham, UK, SN13 9FU

  • Quantum Aseptic Services
    supplier

    Quantum House, Hobson Industrial Estate, Burnopfield, Co.Durham, Burnopfield, UK, NE16 6EA

  • The High Court
    reviewBody

    Strand, London, WC2A 2LL
    generaloffice@administrativecourtoffice.justice.gov.uk
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published